News from Canada

Mij said:
First brain-heart guidelines calls for integrated care for heart, brain and mental health

Ottawa, March 30, 2026 — A new Canadian clinical practice guideline developed through the Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) and led by researchers at the Ottawa Heart Institute is calling on clinicians to treat heart, brain and mental health conditions together rather than in isolation.

I'm glad they are finally acknowledging that the brain is connected to the rest of the body.
Click to expand...
Hopefully this goes in the direction of de-psychologising psychiatric conditions and not in the direction of psychologising cardiovascular and neurological conditions.
 
Sanofi becomes market authorization holder for Nuvaxovid in Canada, expanding COVID-19 vaccine choices for Canadians

News provided by
Sanofi-Aventis Canada Inc.
Apr 09, 2026

  • Nuvaxovid, a non-mRNA COVID-19 vaccine, will be made available in Canada by Sanofi for the fall 2026-2027 season
  • Provincial and territorial availability will be confirmed pending ongoing discussions and provincial assessments
  • Transfer of market authorization from Novavax follows the strategic agreement signed between the two companies in May 2024
  • This underscores Sanofi's commitment to public health and vaccine innovation in Canada
TORONTO, April 9, 2026 /CNW/ - Sanofi today announces it has become the market authorization holder in Canada for Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine. Nuvaxovid represents another step in Sanofi's commitment to building a diverse portfolio of best-in-class vaccines and addressing respiratory diseases for Canadians across their lifespan.

Sanofi will make Nuvaxovid available in Canada for the fall 2026-2027 season.

"With the launch of Nuvaxovid, a non-mRNA protein-based COVID-19 vaccine, Sanofi is now able to offer Canadians greater choice when it comes to COVID-19 protection. The availability of Nuvaxovid means that every Canadian will have the opportunity to access their personal COVID-19 vaccine choice," said Delphine Lansac, General Manager, Canada, Vaccines at Sanofi. "Canadians have clearly expressed a need for a non-mRNA option when it comes to COVID-19 protection. With this transfer, Sanofi can now respond to that need."

Nuvaxovid is a non-mRNA, protein-based vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.1 It has been shown to have a favourable tolerability profile suitable for seasonal vaccination2-4. The vaccine uses a well-established protein-based technology platform and has also demonstrated efficacy of approximately 90% in preventing symptomatic COVID-19 based on pivotal phase 3 clinical studies

​

 
You must log in or register to reply here.
Back
Top Bottom